|
US20110196039A9
(en)
*
|
1994-10-05 |
2011-08-11 |
Kaesemeyer Wayne H |
Controlled release arginine formulations
|
|
DE19545257A1
(de)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
|
|
EP0998940A1
(en)
*
|
1998-09-30 |
2000-05-10 |
Laboratoire Theramex |
Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues
|
|
AU1797800A
(en)
|
1998-12-15 |
2000-07-03 |
Takeda Chemical Industries Ltd. |
Process for producing polymer
|
|
EP1161257A2
(en)
|
1999-03-17 |
2001-12-12 |
Novartis AG |
Pharmaceutical compositions comprising tgf-beta
|
|
HK1042237A1
(en)
|
1999-07-15 |
2002-08-09 |
Takeda Chemical Industries, Ltd. |
Sustained release compositions, process for producing the same and use thereof
|
|
US6303138B1
(en)
|
1999-09-17 |
2001-10-16 |
Depuy Orthopaedics |
Endothelin-based compositions for enhancing connective tissue repair
|
|
JP4361710B2
(ja)
|
2000-04-19 |
2009-11-11 |
ジェネンテック・インコーポレーテッド |
徐放製剤
|
|
US20020010150A1
(en)
*
|
2000-04-28 |
2002-01-24 |
Cortese Stephanie M. |
Homostatic compositions of polyacids and polyalkylene oxides and methods for their use
|
|
US20050042194A1
(en)
|
2000-05-11 |
2005-02-24 |
A.P. Pharma, Inc. |
Semi-solid delivery vehicle and pharmaceutical compositions
|
|
JP2002003406A
(ja)
*
|
2000-06-21 |
2002-01-09 |
Sankyo Co Ltd |
脳血管攣縮予防製剤
|
|
ES2256276T5
(es)
|
2000-08-07 |
2011-02-22 |
Wako Pure Chemical Industries, Ltd. |
Polímero de ácido láctico y procedimiento para su producción.
|
|
AU2002232824A1
(en)
|
2000-12-21 |
2002-07-01 |
Inhale Therapeutic Systems, Inc. |
Induced phase transition method for the production of microparticles containing hydrophobic active agents
|
|
GB0100761D0
(en)
|
2001-01-11 |
2001-02-21 |
Biocompatibles Ltd |
Drug delivery from stents
|
|
DE60231862D1
(de)
*
|
2001-02-23 |
2009-05-20 |
Genentech Inc |
Erodierbare polymere zur injektion
|
|
US6558702B2
(en)
*
|
2001-04-13 |
2003-05-06 |
Alkermes Controlled Therapeutics, Inc. |
Method of modifying the release profile of sustained release compositions
|
|
US20040235748A1
(en)
*
|
2001-04-25 |
2004-11-25 |
Yasutaka Igari |
Agents for preventing postoperative recurrence of premenopausal breast cancer
|
|
PT1397155E
(pt)
*
|
2001-06-21 |
2015-12-07 |
Genentech Inc |
Formulação de libertação sustentada
|
|
TW200526267A
(en)
*
|
2001-06-29 |
2005-08-16 |
Takeda Chemical Industries Ltd |
Controlled release composition and method of producing the same
|
|
GB0122113D0
(en)
*
|
2001-09-11 |
2001-10-31 |
Astrazeneca Ab |
Composition
|
|
EP1460992B1
(en)
*
|
2001-12-03 |
2009-03-11 |
Dor Biopharma, Inc. |
Stabilized reverse micelle compositions and uses thereof
|
|
JP2003192773A
(ja)
*
|
2001-12-26 |
2003-07-09 |
Mitsui Chemicals Inc |
生体吸収性ポリヒドロキシカルボン酸及びその製造法
|
|
WO2003075958A1
(fr)
*
|
2002-03-11 |
2003-09-18 |
Takeda Chemical Industries, Ltd. |
Medicaments permettant de traiter une maladie dependant d'une hormone sexuelle
|
|
KR101041767B1
(ko)
*
|
2002-06-25 |
2011-06-17 |
다케다 야쿠힌 고교 가부시키가이샤 |
서방성 조성물의 제조 방법
|
|
WO2004081196A2
(en)
*
|
2003-03-11 |
2004-09-23 |
Qlt Usa Inc. |
Formulations for cell- schedule dependent anticancer agents
|
|
JP4898431B2
(ja)
*
|
2003-04-29 |
2012-03-14 |
ザ ジェネラル ホスピタル コーポレイション |
複数薬物の持続放出のための方法およびデバイス
|
|
US20040244806A1
(en)
*
|
2003-06-09 |
2004-12-09 |
Ferree Bret A. |
Treating disc herniation and other conditions with leukocytes
|
|
US20090214644A1
(en)
*
|
2003-07-31 |
2009-08-27 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
|
US20050025825A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
|
CN1819821B
(zh)
|
2003-08-08 |
2010-10-13 |
拜奥维尔实验室国际股份有限公司 |
盐酸安非他酮的改良释放片剂
|
|
GB0320806D0
(en)
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20050112170A1
(en)
*
|
2003-11-20 |
2005-05-26 |
Hossainy Syed F. |
Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
|
|
US8846069B2
(en)
*
|
2003-11-20 |
2014-09-30 |
Abbott Cardiovascular Systems Inc. |
Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
|
|
TW200529890A
(en)
*
|
2004-02-10 |
2005-09-16 |
Takeda Pharmaceutical |
Sustained-release preparations
|
|
US20090215898A1
(en)
*
|
2004-03-04 |
2009-08-27 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
|
US20050245614A1
(en)
*
|
2004-03-04 |
2005-11-03 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
|
US7947739B2
(en)
|
2004-03-04 |
2011-05-24 |
Ferring B.V. |
Tranexamic acid formulations
|
|
US20050244495A1
(en)
*
|
2004-03-04 |
2005-11-03 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
|
US8022106B2
(en)
*
|
2004-03-04 |
2011-09-20 |
Ferring B.V. |
Tranexamic acid formulations
|
|
US20060094651A1
(en)
*
|
2004-11-03 |
2006-05-04 |
Cyrus Karkaria |
Formulations and methods of production of FGF-20
|
|
PL1768650T3
(pl)
|
2004-06-04 |
2009-01-30 |
Camurus Ab |
Ciekłe formulacje depot
|
|
WO2005122734A2
(en)
*
|
2004-06-14 |
2005-12-29 |
The Research Foundation Of State University Of New York |
Nanosphere/microsphere delivery system for the treatment of spinal cord injury
|
|
TW200613012A
(en)
*
|
2004-07-02 |
2006-05-01 |
Takeda Pharmaceuticals Co |
Sustained-release composition, process for producing the same and use of the same
|
|
US20060039890A1
(en)
*
|
2004-08-20 |
2006-02-23 |
Renshaw Perry F |
Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
|
|
US20060068010A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Stephen Turner |
Method for improving the bioavailability of orally delivered therapeutics
|
|
US8313763B2
(en)
*
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
|
CA2582374A1
(en)
*
|
2004-10-04 |
2006-04-20 |
Qlt Usa, Inc. |
Ocular delivery of polymeric delivery formulations
|
|
US9649382B2
(en)
|
2005-01-14 |
2017-05-16 |
Camurus Ab |
Topical bioadhesive formulations
|
|
PL1845942T3
(pl)
*
|
2005-01-14 |
2014-07-31 |
Camurus Ab |
Preparaty analogu GnRH
|
|
EP1843746B1
(en)
*
|
2005-01-14 |
2011-03-16 |
Camurus Ab |
Somatostatin analogue formulations
|
|
AU2005325510B2
(en)
*
|
2005-01-21 |
2009-07-02 |
Camurus Ab |
Pharmaceutical lipid compositions
|
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
|
JP5242375B2
(ja)
|
2005-04-01 |
2013-07-24 |
ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア |
ホスホノ−ペント−２−エン−１−イルヌクレオシド及び類似体
|
|
US7342048B2
(en)
|
2005-04-28 |
2008-03-11 |
Nipro Corporation |
Bioabsorbable pharmaceutical formulation
|
|
US8097239B2
(en)
*
|
2005-06-06 |
2012-01-17 |
Camurus Ab |
Controlled-release formulations
|
|
PL1888031T3
(pl)
*
|
2005-06-06 |
2013-04-30 |
Camurus Ab |
Preparaty analogu glp-1
|
|
US20100310670A1
(en)
*
|
2005-09-02 |
2010-12-09 |
Takeda Pharmaceutical Company Limited |
Sustained-release microsphere containing short chain deoxyribonucleic acid or short chain ribonucleic acid and method of producing the same
|
|
SI1787658T1
(sl)
|
2005-11-10 |
2012-07-31 |
Chemi Spa |
Formulacije z trajnim sproščanjem somatostatin analognih inhibitorjev rastnega hormona
|
|
CA2841386A1
(en)
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
|
WO2007106468A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Formulations of sitaxsentan sodium
|
|
AU2007225088B2
(en)
|
2006-03-13 |
2012-09-13 |
Kyorin Pharmaceutical Co., Ltd |
Aminoquinolones as GSK-3 inhibitors
|
|
BRPI0708879A2
(pt)
*
|
2006-03-13 |
2011-06-14 |
Encysive Pharmaceuticals |
peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
MX2009002960A
(es)
|
2006-09-21 |
2009-06-26 |
Activx Biosciences Inc |
Inhibidores de serina hidrolasa.
|
|
WO2008049116A2
(en)
|
2006-10-19 |
2008-04-24 |
Auspex Pharmaceuticals, Inc. |
Substituted indoles
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
US7713541B1
(en)
|
2006-11-21 |
2010-05-11 |
Abbott Cardiovascular Systems Inc. |
Zwitterionic terpolymers, method of making and use on medical devices
|
|
MY148370A
(en)
|
2006-12-18 |
2013-04-15 |
Takeda Pharmaceutical |
Sustained-release composition and method for producing the same
|
|
US8974801B2
(en)
*
|
2006-12-21 |
2015-03-10 |
Amphastar Pharmaceuticals Inc. |
Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
|
|
CN101611008A
(zh)
*
|
2006-12-22 |
2009-12-23 |
恩希赛弗制药公司 |
C3a受体调节剂及其使用方法
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
WO2008106166A2
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
|
|
CA2680912C
(en)
|
2007-03-15 |
2017-11-14 |
Auspex Pharmaceuticals, Inc. |
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
|
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
|
GB0711656D0
(en)
|
2007-06-15 |
2007-07-25 |
Camurus Ab |
Formulations
|
|
JP2010533205A
(ja)
*
|
2007-07-12 |
2010-10-21 |
トラガラ ファーマシューティカルズ，インク． |
癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
|
|
GB0716385D0
(en)
|
2007-08-22 |
2007-10-03 |
Camurus Ab |
Formulations
|
|
CA2699151A1
(en)
*
|
2007-09-11 |
2009-03-19 |
Activx Biosciences, Inc. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
|
|
KR101597841B1
(ko)
|
2007-09-12 |
2016-02-26 |
교린 세이야꾸 가부시키 가이샤 |
Ｇｓｋ-３ 억제제로서의 스피로시클릭 아미노퀴놀론
|
|
ES2528409T3
(es)
|
2007-10-24 |
2015-02-10 |
Camurus Ab |
Formulaciones de liberación controlada
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
AU2009226136B2
(en)
|
2008-03-17 |
2013-08-15 |
Ambit Biosciences Corporation |
Quinazoline derivatives as RAF kinase modulators and methods of use thereof
|
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
|
RU2010151944A
(ru)
*
|
2008-05-20 |
2012-06-27 |
Серенис Терапьютикс С.А. (Fr) |
Ниацин и нспвс для комбинированной терапии
|
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
|
CA2730760A1
(en)
*
|
2008-07-16 |
2010-01-21 |
Surmodics Pharmaceuticals, Inc. |
Process for preparing microparticles containing bioactive peptides
|
|
GB0815435D0
(en)
|
2008-08-22 |
2008-10-01 |
Camurus Ab |
Formulations
|
|
JP2012512163A
(ja)
*
|
2008-12-11 |
2012-05-31 |
エーピー ファーマ， インコーポレイテッド |
ポリオルトエステルおよびそれらの製剤の安定性を高めるための方法
|
|
US8536114B2
(en)
|
2008-12-31 |
2013-09-17 |
Scynexis, Inc. |
Macrocycles
|
|
EP2601934A1
(en)
|
2009-01-22 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Vesicular phospholipid gels comprising proteinaceous substances
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
CA2752885A1
(en)
|
2009-02-27 |
2010-09-02 |
Ambit Biosciences Corporation |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
|
WO2010101967A2
(en)
|
2009-03-04 |
2010-09-10 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole hcv polymerase inhibitors
|
|
JP2012520314A
(ja)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
|
|
CA2755120C
(en)
*
|
2009-03-11 |
2017-05-16 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as gsk-3 inhibitors
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
CA2756067A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
KR101687144B1
(ko)
|
2009-04-22 |
2016-12-15 |
액시킨 파마수티컬스 인코포레이티드 |
2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
|
|
EP2727908A3
(en)
|
2009-04-22 |
2014-08-20 |
Axikin Pharmaceuticals, Inc. |
2,5-disubstituted arylsulfonamide CCR3 antagonists
|
|
CN102459210B
(zh)
|
2009-04-22 |
2015-09-02 |
埃克希金医药品有限公司 |
芳基磺酰胺ccr3拮抗剂
|
|
US20100280117A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Xanodyne Pharmaceuticals, Inc. |
Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
|
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
|
CA2767008C
(en)
|
2009-07-07 |
2018-01-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
JP5905387B2
(ja)
|
2009-07-08 |
2016-04-20 |
ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズＨｏｐｅ Ｍｅｄｉｃａｌ Ｅｎｔｅｒｐｒｉｓｅｓ，Ｉｎｃ．Ｄｂａ Ｈｏｐｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ |
チオ硫酸ナトリウムを含有する薬学的組成物
|
|
EP2467144A1
(en)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
|
AR077712A1
(es)
|
2009-08-05 |
2011-09-14 |
Idenix Pharmaceuticals Inc |
Inhibidores de serina proteasa macrociclica
|
|
KR20120059558A
(ko)
|
2009-08-19 |
2012-06-08 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 화합물 및 이의 사용 방법
|
|
TW201120037A
(en)
*
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
MY159958A
(en)
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
|
CA2785978A1
(en)
|
2009-12-30 |
2011-07-07 |
Scynexis, Inc. |
Cyclosporine analogues
|
|
WO2011089167A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
|
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
|
US9205577B2
(en)
*
|
2010-02-05 |
2015-12-08 |
Allergan, Inc. |
Porogen compositions, methods of making and uses
|
|
US9120815B2
(en)
|
2010-02-05 |
2015-09-01 |
Tragara Pharmaceuticals, Inc. |
Solid state forms of macrocyclic kinase inhibitors
|
|
US9138309B2
(en)
|
2010-02-05 |
2015-09-22 |
Allergan, Inc. |
Porous materials, methods of making and uses
|
|
SG183257A1
(en)
|
2010-02-11 |
2012-09-27 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
AU2011223873B2
(en)
|
2010-03-02 |
2015-06-25 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
MX336559B
(es)
|
2010-03-17 |
2016-01-25 |
Axikin Pharmaceuticals Inc |
Antagonistas de ccr3 de arilsulfonamida.
|
|
US11202853B2
(en)
*
|
2010-05-11 |
2021-12-21 |
Allergan, Inc. |
Porogen compositions, methods of making and uses
|
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
|
WO2011153197A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
|
|
AU2011261501B2
(en)
|
2010-06-01 |
2016-01-21 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
|
|
EP2576532B1
(en)
|
2010-06-07 |
2018-07-18 |
Novomedix, LLC |
Furanyl compounds and the use thereof
|
|
WO2012012370A1
(en)
|
2010-07-19 |
2012-01-26 |
Summa Health System |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
|
US20130317045A1
(en)
|
2010-09-01 |
2013-11-28 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
|
EP2611809A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
MX2013002383A
(es)
|
2010-09-01 |
2013-07-05 |
Ambit Biosciences Corp |
Sales bromhidrato de una pirazolilaminoquinazolina.
|
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
US20130225615A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
US8703943B2
(en)
|
2010-09-01 |
2014-04-22 |
Ambit Biosciences Corporation |
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
WO2012030944A2
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline compounds and methods of use thereof
|
|
EP2611789A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
WO2012030918A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
US20120088769A1
(en)
|
2010-10-11 |
2012-04-12 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
JP2014500275A
(ja)
|
2010-12-06 |
2014-01-09 |
フォリカ，インコーポレイテッド |
禿頭症を治療するため、および毛髪の成長を促進するための方法
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
EP3238722B1
(en)
|
2011-01-10 |
2019-03-13 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones
|
|
JP2014503597A
(ja)
|
2011-01-31 |
2014-02-13 |
セルジーン コーポレイション |
シチジンアナログの医薬組成物及びその使用方法
|
|
TW201244737A
(en)
|
2011-02-03 |
2012-11-16 |
Alexion Pharma Inc |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
|
|
SI2683384T1
(sl)
|
2011-03-11 |
2016-05-31 |
Celgene Corporation |
Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
|
|
CN107501241B
(zh)
|
2011-03-28 |
2020-10-13 |
梅制药公司 |
化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
|
|
EP2691388A1
(en)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
CA2831590A1
(en)
|
2011-03-28 |
2012-10-04 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
KR20140042868A
(ko)
|
2011-06-23 |
2014-04-07 |
맵 파마슈티컬스, 인코포레이티드 |
신규한 플루오로에르골린 유사체
|
|
WO2013003157A1
(en)
|
2011-06-28 |
2013-01-03 |
Yale University |
Cell-free tissued engineered vascular grafts
|
|
EP2734520B1
(en)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US9056877B2
(en)
|
2011-07-19 |
2015-06-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
PE20141371A1
(es)
|
2011-08-29 |
2014-10-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
|
US9403863B2
(en)
|
2011-09-12 |
2016-08-02 |
Idenix Pharmaceuticals Llc |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
|
AU2012308900A1
(en)
|
2011-09-12 |
2013-05-09 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
|
KR102066297B1
(ko)
|
2011-10-14 |
2020-01-14 |
암비트 바이오사이언시즈 코포레이션 |
헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
|
|
AR089650A1
(es)
|
2011-10-14 |
2014-09-10 |
Idenix Pharmaceuticals Inc |
Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
|
|
US8586527B2
(en)
|
2011-10-20 |
2013-11-19 |
Jaipal Singh |
Cerivastatin to treat pulmonary disorders
|
|
US9555118B2
(en)
|
2011-12-05 |
2017-01-31 |
Camrus Ab |
Robust controlled-release peptide formulations
|
|
EP2793580A4
(en)
|
2011-12-19 |
2015-05-20 |
Map Pharmaceuticals Inc |
NEW DERIVATIVES OF ISO-ERGOLINE
|
|
AU2012355983A1
(en)
|
2011-12-21 |
2015-01-22 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
|
SG10201606063RA
(en)
|
2012-01-23 |
2016-09-29 |
Sage Therapeutics Inc |
Neuroactive steroid formulations and methods of treating cns disorders
|
|
US9611253B2
(en)
|
2012-02-29 |
2017-04-04 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
CN104302640A
(zh)
|
2012-03-16 |
2015-01-21 |
埃克希金医药品有限公司 |
3,5-二氨基吡唑激酶抑制剂
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
MD20140134A2
(ro)
|
2012-05-22 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
|
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
PE20150195A1
(es)
|
2012-05-25 |
2015-02-27 |
Camarus Ab |
Formulaciones de agonistas del receptor de somatostatina
|
|
CA2985787A1
(en)
|
2012-06-07 |
2013-12-12 |
Georgia State University Research Foundation, Inc. |
Seca inhibitors and methods of making and using thereof
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
ES2837803T3
(es)
|
2012-07-26 |
2021-07-01 |
Camurus Ab |
Formulaciones de opioides
|
|
AU2013294915C1
(en)
|
2012-07-26 |
2019-11-21 |
Camurus Ab |
Opioid formulations
|
|
KR20210073616A
(ko)
|
2012-08-09 |
2021-06-18 |
셀진 코포레이션 |
면역-관련 및 염증성 질환의 치료
|
|
LT2882737T
(lt)
|
2012-08-09 |
2019-04-25 |
Celgene Corporation |
(s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma
|
|
RS62761B1
(sr)
|
2012-08-21 |
2022-01-31 |
Sage Therapeutics Inc |
Alopregnanolon za lečenje refraktornog epileptičkog statusa
|
|
EP2890370B1
(en)
|
2012-08-31 |
2019-10-09 |
The Regents of the University of California |
Agents useful for treating obesity, diabetes and related disorders
|
|
BR112015004959A2
(pt)
|
2012-09-07 |
2017-07-04 |
Axikin Pharmaceuticals Inc |
composto isotopicamente enriquecido, composição farmacêutica, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença, distúrbio ou condição mediada por ccr3, relacionada a eosinófilos, relacionada a basófilos, relacionada a mastócitos ou relacionada a mastócitos em um sujeito, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença inflamatória em um sujeito e método para modular a atividade de ccr3.
|
|
CN111529535A
(zh)
|
2012-09-27 |
2020-08-14 |
儿童医学中心公司 |
用于治疗肥胖症的化合物和其使用方法
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
ES2674980T3
(es)
|
2012-10-08 |
2018-07-05 |
Idenix Pharmaceuticals Llc |
Análogos de 2'-cloro nucleósidos para infección por VHC
|
|
EP2909223B1
(en)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinucleotide compounds for hcv infection
|
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
|
RU2702908C2
(ru)
|
2012-11-01 |
2019-10-14 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
|
EP2916830A2
(en)
|
2012-11-08 |
2015-09-16 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
|
WO2014078427A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
|
WO2014085633A1
(en)
|
2012-11-30 |
2014-06-05 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
|
AU2013361340A1
(en)
|
2012-12-21 |
2015-07-09 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
|
AU2014205324A1
(en)
|
2013-01-11 |
2015-07-30 |
Mayo Foundation For Medical Education And Research |
Vitamins C and K for treating polycystic diseases
|
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
KR20160013204A
(ko)
|
2013-05-30 |
2016-02-03 |
인피니티 파마슈티칼스, 인코포레이티드 |
Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
|
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
WO2015031613A1
(en)
|
2013-08-30 |
2015-03-05 |
Ambit Biosciences Corporation |
Biaryl acetamide compounds and methods of use thereof
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015051336A1
(en)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3964507A1
(en)
|
2013-10-04 |
2022-03-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
|
PT3074033T
(pt)
|
2013-11-26 |
2019-02-08 |
Childrens Medical Ct Corp |
Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
|
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
JP2017504572A
(ja)
|
2013-11-27 |
2017-02-09 |
アイデニクス・ファーマシューティカルズ・エルエルシー |
肝臓癌治療のためのヌクレオチド類
|
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
CN106456628A
(zh)
|
2014-03-19 |
2017-02-22 |
无限药品股份有限公司 |
用于治疗PI3K‑γ介导的障碍的杂环化合物
|
|
IL291000B2
(en)
|
2014-03-20 |
2024-04-01 |
Capella Therapeutics Inc |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
|
CA2943231C
(en)
|
2014-03-20 |
2023-10-24 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
|
US20170209408A1
(en)
|
2014-04-03 |
2017-07-27 |
The Children's Medical Center Corporation |
Hsp90 inhibitors for the treatment of obesity and methods of use thereof
|
|
CA2944549A1
(en)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxin useful for the treatment of pain
|
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
|
MX2016014731A
(es)
|
2014-05-12 |
2017-05-04 |
Conatus Pharmaceuticals Inc |
Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
|
|
AU2015265607A1
(en)
|
2014-05-28 |
2016-11-17 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
|
WO2015195474A1
(en)
|
2014-06-18 |
2015-12-23 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
CA2949793C
(en)
|
2014-06-19 |
2024-02-27 |
Ariad Pharmaceuticals, Inc. |
Heteroaryl compounds for kinase inhibition
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
AU2015314830B2
(en)
|
2014-09-12 |
2021-01-07 |
Tobira Therapeutics, Inc. |
Cenicriviroc combination therapy for the treatment of fibrosis
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
PT3209647T
(pt)
|
2014-10-21 |
2020-09-10 |
Ariad Pharma Inc |
Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
|
|
US20170354639A1
(en)
|
2014-10-24 |
2017-12-14 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
MY191736A
(en)
|
2014-12-23 |
2022-07-13 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
|
MX2017009406A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo isoergolina y usos de estos.
|
|
JP6856532B2
(ja)
|
2015-01-20 |
2021-04-07 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ |
エルゴリン化合物およびその使用
|
|
EP3303361A1
(en)
|
2015-05-27 |
2018-04-11 |
Idenix Pharmaceuticals LLC |
Nucleotides for the treatment of cancer
|
|
US20190015396A1
(en)
|
2015-06-23 |
2019-01-17 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
|
US10471055B2
(en)
|
2015-08-17 |
2019-11-12 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
AU2016329201A1
(en)
|
2015-09-30 |
2018-04-26 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
DK3368534T3
(da)
|
2015-10-30 |
2021-02-15 |
Neurocrine Biosciences Inc |
Valbenazin-ditosylat og polymorfer deraf
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
CN122562777A
(zh)
|
2015-12-02 |
2026-08-14 |
阿斯特来亚治疗有限责任公司 |
哌啶基痛敏肽受体化合物
|
|
DK3394057T3
(da)
|
2015-12-23 |
2022-04-11 |
Neurocrine Biosciences Inc |
Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
|
|
KR20180101418A
(ko)
|
2015-12-31 |
2018-09-12 |
코나터스 파마슈티칼스, 인크. |
간 질환의 치료에서의 카스파제 억제제의 사용 방법
|
|
EP3399980B1
(en)
|
2016-01-08 |
2025-07-16 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
|
CA3010794A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
TWI782395B
(zh)
|
2016-01-08 |
2022-11-01 |
美商西建公司 |
抗增生化合物，及其醫藥組合物及用途
|
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
AU2017250086A1
(en)
|
2016-04-11 |
2018-09-20 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
US11497738B2
(en)
|
2016-04-29 |
2022-11-15 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3510027B1
(en)
|
2016-09-07 |
2022-11-02 |
FGH BioTech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
|
HRP20210544T1
(hr)
|
2016-11-03 |
2021-08-20 |
Kura Oncology, Inc. |
Inhibitori farneziltransferaze za uporabu u liječenju raka
|
|
CN110167542A
(zh)
|
2016-11-09 |
2019-08-23 |
诺沃梅迪科斯有限公司 |
1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
|
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
WO2018102455A1
(en)
|
2016-12-01 |
2018-06-07 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
|
TW202515564A
(zh)
|
2016-12-02 |
2025-04-16 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
KR20230170136A
(ko)
|
2017-01-27 |
2023-12-18 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
WO2018156609A1
(en)
|
2017-02-21 |
2018-08-30 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
EP3601326A4
(en)
|
2017-03-20 |
2020-12-16 |
The Broad Institute, Inc. |
COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION
|
|
CN110799192A
(zh)
|
2017-03-27 |
2020-02-14 |
加利福尼亚大学董事会 |
治疗癌症的组合物和方法
|
|
JP2020515611A
(ja)
|
2017-03-29 |
2020-05-28 |
サイトワン セラピューティクス， インコーポレイテッド |
疼痛の処置のための１１，１３−修飾サキシトキシン
|
|
CA3058214A1
(en)
|
2017-03-29 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
11,13-modified saxitoxins for the treatment of pain
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
ES2913213T3
(es)
|
2017-05-19 |
2022-06-01 |
Nflection Therapeutics Inc |
Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
|
|
JP7212956B2
(ja)
|
2017-05-19 |
2023-01-26 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置用のピロロピリジン－アニリン化合物
|
|
CA3064274A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
|
JP2020528900A
(ja)
|
2017-07-27 |
2020-10-01 |
アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ |
体脂肪低減のためのプロスタサイクリン受容体アゴニスト
|
|
CA3071854A1
(en)
|
2017-08-07 |
2019-02-14 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2019051477A1
(en)
|
2017-09-11 |
2019-03-14 |
Sage Therapeutics, Inc. |
METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
|
|
CA3076000A1
(en)
|
2017-09-21 |
2019-03-28 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
KR20260033622A
(ko)
|
2017-10-04 |
2026-03-10 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
면역조절성 올리고사카라이드
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
US20200230127A1
(en)
|
2017-10-10 |
2020-07-23 |
Neurocrine Biosciences, Inc. |
Methods for the Administration of Certain VMAT2 Inhibitors
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
AU2019207491A1
(en)
|
2018-01-10 |
2020-07-30 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
|
JOP20200298A1
(ar)
|
2018-06-14 |
2020-11-22 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
|
|
US11447497B2
(en)
|
2018-06-29 |
2022-09-20 |
Histogen, Inc. |
(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
EP3860714B1
(en)
|
2018-10-03 |
2023-09-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
AU2019372141A1
(en)
|
2018-11-01 |
2021-05-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
CN113660931B
(zh)
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
|
|
EP3883552B1
(en)
|
2018-11-20 |
2025-04-09 |
NFlection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
|
CN113645964B
(zh)
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
|
|
CN113473986B
(zh)
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病萘啶酮苯胺化合物
|
|
JP7407461B2
(ja)
|
2018-12-19 |
2024-01-04 |
シャイ・セラピューティクス・エルエルシー |
がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
|
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
|
US20220071941A1
(en)
|
2018-12-21 |
2022-03-10 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
|
CN113874080B
(zh)
|
2019-02-06 |
2024-09-27 |
戴斯阿尔法公司 |
Il-17a调节剂及其用途
|
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
AU2020231396B2
(en)
|
2019-03-07 |
2025-03-20 |
Nobo Medicine Inc. |
Caspase inhibitors and methods of use thereof
|
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020205486A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
WO2021007478A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
|
EP3996813A1
(en)
|
2019-07-11 |
2022-05-18 |
Cura Therapeutics, LLC |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
EP4003314B1
(en)
|
2019-07-26 |
2024-07-10 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
AU2020342591A1
(en)
|
2019-09-02 |
2022-03-03 |
Camurus Ab |
Formulations and treatment methods
|
|
JP7566889B2
(ja)
|
2019-09-16 |
2024-10-15 |
ダイス・アルファ・インコーポレイテッド |
Ｉｌ－１７ａモジュレーターおよびその使用
|
|
EP4034236A1
(en)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Compounds useful for treating liver diseases
|
|
MX2022003929A
(es)
|
2019-10-01 |
2022-06-14 |
Molecular Skin Therapeutics Inc |
Compuestos de benzoxazinona como inhibidores dobles de klk5/7.
|
|
JP7600528B2
(ja)
*
|
2020-03-16 |
2024-12-17 |
株式会社リコー |
粒子の製造方法
|
|
CA3179635A1
(en)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
US12024521B2
(en)
|
2020-06-30 |
2024-07-02 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
|
EP4196482B1
(en)
|
2020-08-14 |
2025-10-01 |
SiteOne Therapeutics, Inc. |
Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
|
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
IL305752A
(en)
|
2021-03-10 |
2023-11-01 |
Dice Molecules Sv Inc |
INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
|
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
CA3236150A1
(en)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
IL312132A
(en)
|
2021-11-30 |
2024-06-01 |
Kura Oncology Inc |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
|
EP4433040A4
(en)
|
2022-01-03 |
2025-11-12 |
Lilac Therapeutics Inc |
ACYCLIC THIOL PRODRUGS
|
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
CN114404663A
(zh)
*
|
2022-01-07 |
2022-04-29 |
浙江瑞谷生物科技有限公司 |
一种具有炎症缓解特性的骨修复材料及其制备方法
|
|
CN114404664A
(zh)
*
|
2022-02-17 |
2022-04-29 |
浙江瑞谷生物科技有限公司 |
一种具备长效缓释的骨修复支架材料及其制备方法及应用
|
|
JP2025507621A
(ja)
|
2022-03-02 |
2025-03-21 |
ミトパワー， インク． |
ニコチン酸及びリボースから誘導体化した新規プロドラッグ
|
|
US12187732B2
(en)
|
2022-03-28 |
2025-01-07 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
|
AU2023245901A1
(en)
|
2022-03-30 |
2024-10-03 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
EP4508044A1
(en)
|
2022-04-14 |
2025-02-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
|
CA3256486A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic Na V1.8 Heterocyclic Amide Inhibitors for Pain Management
|
|
EP4519439A1
(en)
|
2022-05-05 |
2025-03-12 |
BioMarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
|
JP2025531869A
(ja)
|
2022-09-09 |
2025-09-25 |
イノヴォ セラピューティクス、インコーポレイテッド |
ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
|
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
|
US20240139187A1
(en)
|
2022-10-12 |
2024-05-02 |
The Children's Medical Center Corporation |
Selective hypothalamus permeable hdac6 inhibitors for treatment of leptin-resistant obesity
|
|
IL320183A
(en)
|
2022-10-18 |
2025-06-01 |
Eluciderm Inc |
2-Substituted 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES for wound treatment
|
|
EP4608834A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing pyridine compounds
|
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
EP4608839A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
US20260193236A1
(en)
|
2022-11-30 |
2026-07-09 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
EP4626865A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
AU2023418987A1
(en)
|
2022-12-30 |
2025-07-03 |
Altay Therapeutics, Inc. |
2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
|
|
JP2026516311A
(ja)
|
2023-04-24 |
2026-05-21 |
バイオマリン ファーマシューティカル インコーポレイテッド |
Ｓｔｘｂｐ１障害を治療するための組成物および方法
|
|
WO2024233303A1
(en)
|
2023-05-05 |
2024-11-14 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
AU2024344247A1
(en)
|
2023-09-19 |
2026-05-07 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
WO2025072489A2
(en)
|
2023-09-27 |
2025-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
|
|
CN122003411A
(zh)
|
2023-09-27 |
2026-05-08 |
爱索斯特里克斯公司 |
Myst抑制剂
|
|
KR20260094777A
(ko)
|
2023-10-16 |
2026-06-23 |
브리스톨-마이어스 스큅 컴퍼니 |
Gspt1 화합물 및 상기 화합물의 사용 방법
|
|
KR20260100334A
(ko)
|
2023-10-20 |
2026-06-29 |
알타이 테라퓨틱스, 인크. |
신경근육 장애 등의 치료를 위한 dux4 억제제로서의 n-페닐-3-(2,5-디옥소피롤리딘-1-일)프로판아미드 유도체 및 유사 화합물
|
|
WO2025102082A1
(en)
|
2023-11-10 |
2025-05-15 |
Altay Therapeutics, Inc. |
Carbocyclic and heterocyclic stat3 inhibitor compositions and methods
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
AU2025206198A1
(en)
|
2024-01-04 |
2026-07-23 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
AU2025211735A1
(en)
|
2024-01-24 |
2026-07-16 |
Siteone Therapeutics, Inc. |
2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025221809A1
(en)
|
2024-04-16 |
2025-10-23 |
Eluciderm Inc. |
2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases
|
|
TW202604501A
(zh)
|
2024-05-17 |
2026-02-01 |
美商賽特溫治療公司 |
用於治療疼痛之ＮＡｖ１．８之經取代之環烷基及雜環烷基抑制劑
|
|
WO2025255341A1
(en)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Tetrahydrofuranyl ire1/xbp1s activators
|
|
LU605402B1
(en)
|
2024-07-11 |
2026-07-14 |
Sea4Us Biotecnologia E Recursos Marinhos Sa |
Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
|
|
WO2026120283A1
(en)
|
2024-12-06 |
2026-06-11 |
Celgene Corporation |
Assessing subjects having acute st-elevation myocardial infarctions
|